GeoVax Labs vs MediciNova
GOVX and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOVX and MNOV compare
MediciNova is the larger company, worth 96 times as much as GeoVax Labs ($68.7M against $718K).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOVX | MNOV |
|---|---|---|
| Size and price | ||
| Market cap | $718K | $68.7M |
| Share price | $1.71 | $1.40 |
| Change, 1 year | −86.3% | −11.1% |
| Change, 5 years | −100.0% | −56.5% |
| Beta (5Y) | – | 0.39 |
| Employees | 19 | 6 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 73.4× |
| P/B | 0.6× (better) | 1.7× |
| FCF yield | −2299% | −14.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | 6.4% | – |
| Profitability | ||
| Operating margin | – | −1232% |
| Net margin | – | −1127% |
| FCF margin | – | −1048% |
| Return on equity | −603% | −24.8% (better) |
| Return on invested capital | – | −78.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.46 | 8.75 (better) |
| Altman Z-score | −84.45 | −3.99 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 10.5% |
| Held by insiders | 47.4% | 12.8% |
| Insider net buying, 12 months | $0 (better) | −$1.7M |
| Short interest, % of float | 79.5% | 0.66% |
Go deeper
- GOVX stock overview
- GOVX income statement
- GOVX valuation and score
- MNOV stock overview
- MNOV income statement
- MNOV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.